Bio-Inspired Synthetic Nanovesicles for Glucose-Responsive Release of Insulin by Tai, Wanyi et al.
Bio-Inspired Synthetic Nanovesicles for Glucose-Responsive Release
of Insulin
Wanyi Tai,†,‡ Ran Mo,†,‡ Jin Di,†,‡ Vinayak Subramanian,† Xiao Gu,† John B. Buse,§ and Zhen Gu*,†,‡
†Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University,
Raleigh, North Carolina 27695, United States
‡Center for Nanotechnology in Drug Delivery and Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of
North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
§Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States
*S Supporting Information
ABSTRACT: A new glucose-responsive formulation for self-
regulated insulin delivery was constructed by packing insulin,
glucose-specific enzymes into pH-sensitive polymersome-
based nanovesicles assembled by a diblock copolymer. Glucose
can passively transport across the bilayer membrane of the
nanovesicle and be oxidized into gluconic acid by glucose
oxidase, thereby causing a decrease in local pH. The acidic
microenvironment causes the hydrolysis of the pH sensitive
nanovesicle that in turn triggers the release of insulin in a
glucose responsive fashion. In vitro studies validated that the
release of insulin from nanovesicle was effectively correlated
with the external glucose concentration. In vivo experiments,
in which diabetic mice were subcutaneously administered with the nanovesicles, demonstrate that a single injection of the
developed nanovesicle facilitated stabilization of the blood glucose levels in the normoglycemic state (<200 mg/dL) for up to 5
days.
■ INTRODUCTION
Diabetes mellitus is a type of common metabolic disease in
which glucose is accumulated in the blood, caused either by
pancreas’s failure to produce insulin (Type 1) or by insulin
resistance from the body tissue (Type 2).1 As of 2012, diabetes
affected an estimated 371 million people, which makes up
around 4.9% of the global population.2,3 Long-term exposure to
the high blood glucose (BG) level may cause many
complications, including cardiovascular disease, retinopathy,
chronic kidney disease, and even cancer.4−6 The traditional
medical care for the Type 1 and advanced Type 2 diabetics
requires continuous glucose monitoring and self-administration
of insulin to maintain the normoglycemia. However, self-
administration of insulin always associates with the risk of
hypoglycemia that might cause unconsciousness, brain damage
and death.7 Additionally, it is difficult to achieve a tight control
of BG levels.
A practical approach to reduce the risk described above
would create a closed-loop system that is able to mimic
pancreatic function and automatically “secrete” insulin in
response to the BG levels. One straightforward strategy is a
sensor-augmented insulin pump that combines a continuous
BG monitoring system with an insulin reservoir.8 This
computer-aided device is designed to infuse insulin based on
the feedback of BG level. However, challenges, such as
guaranteeing accurate glucose feedback and preventing failures
in insulin infusion, still persist today. In addition to electronic
devices, chemically controlled closed-loop delivery platforms
have also been explored.9,10 Typically, insulin is embedded in a
matrix consisting of glucose-responsive elements, including
enzymes (glucose oxidase/catalase (GOx/CAT), phenylbor-
onic acid (PBA), or glucose binding proteins).11−25 The matrix
can typically undergo structural fluctuations (shrink or swell)
regulated by glucose concentration changes, subsequently
leading to a glucose-stimulated insulin release. Despite these,
the majority of existing synthetic closed-loop systems has been
limited to in vitro studies, with relatively few showing
applicability in vivo. Challenges remain in order to demonstrate
a method which would combine (1) fast response; (2) ease of
administration, possibly by simple long-lasting injections; and
(3) biocompatibility without long-term side effects.26
We describe here a new glucose-mediated insulin delivery
system using biomimetic polymersome-based nanovesicle.
Polymersome is a self-assembled polymeric capsule, in which
an aqueous core is surrounded by a well-organized amphiphilic
polymeric bilayer.27−30 Composed by high molecular weight
polymer, polymerosme has robust mechanical stability which
can prevent premature loss of its cargo.31 The chemical
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feasibility in block copolymer synthesis also facilitates the
possibility to tune the physical properties of polymersome.32
The boronic acid containing diblock copolymer has been well
synthesized and assembled into a polymersome for sugar-
responsive insulin delivery.22 This PBA-based formulation
showed moderate responsiveness at a relatively high glucose
concentration, which could be limited for in vivo studies. We
have previously reported that GOx/CAT based enzymatic
system exhibits promising improvement of diabetic conditions
in vivo.3,15,16 Gordigo and co-workers also reported that the
GOx/CAT associated membrane-based device with the
capability of regulating the BG levels in vivo.11 However, a
well-defined enzyme-based polymersome vesicle for glucose-
responsive insulin delivery remains elusive.
As depicted in Figure 1A, assembled by the mildly acid-
sensitive diblock copolymer consisting of poly(ethylene glycol)
(PEG) and Ketal-modified polyserine (designated PEG-poly-
(Ser-Ketal); Figure 1B), the polymersome has a nanoscaled
vesicle structure. Cargoes, including recombinant human
insulin, GOx, and CAT, are faithfully encapsulated in the
core with negligible release through the closely packed bilayer
membrane. However, such a robust membrane can allow
glucose to passively transport inside due to the small size and
neutral property of glucose.33 Once its local concentration
increases, glucose diffuses across the membrane and interacts
with GOx in the core, which leads to the catalytic conversion of
glucose to gluconic acid, thereby yielding the decrease of local
pH value. Moreover, CAT assists GOx’s catalysis by breaking
down an undesirable byproduct hydrogen peroxide (H2O2) and
providing oxygen (O2) for further promoting GOx’s catalysis
(Figure S1).15 As a result, the pendant acid-labile ketals on the
polyserine segment of PEG-poly(Ser-Ketal) sheds upon acidic
hydrolysis, which renders the resulting PEG-polyserine water-
soluble. Accompanied by this structural change, the membrane
dissociates, followed by the release of core-encapsulated insulin
(Figure 1A). For the in vivo application, these vesicles can be
integrated with a thermoresponsive and injectable hydrogel-
based matrix for the subcutaneous administration. The final
depot provides a porous but stable three-dimensional (3-D)
scaffold for the long-term insulin delivery in a glucose-mediated
fashion.
■ EXPERIMENTAL SECTION
Materials. All chemicals were obtained from commercial sources
and used without further purification. Glucose oxidase (GOx) and
bovine catalase (CAT) were purchased from Sigma-Aldrich. Poly-
(ethylene glycol) amine (PEG2000-NH2) was ordered from Laysan Bio,
Inc. (U.S.A.). 2-Ethoxy-1-propene was obtained from Synthonix Inc.
Recombinant human insulin (Zn salt, 27.5 IU/mg) was purchased
from Life Technologies (U.S.A.). All the organic solvents for synthesis
and analysis were ordered from Fisher Scientific Inc. and used as
received.
1H NMR spectra were assayed on a Varian Gem2300 (300 MHz)
spectrometer. The spectra were recorded by chemical shift (ppm) and
referenced via the corresponding deuterated solvent. Molecular weight
(Mw) of Oregon Green 488 labeled insulin was analyzed on the AB
Sciex 5800 MALDI-TOF/TOF MS using the sinapic acid as matrix. As
for transmission electron microscopy (TEM), the copper TEM grid
(Ted Pella Inc.) was plasma glow-discharged for 20 s to create a
hydrophilic surface on the carbon surface. A nanovesicle sample (20
μL) was absorbed onto the freshly plasma-discharged carbon
membrane for 30 s and then blotted with filter paper to remove
excess solution. The grid was examined with JEOL 2000FX at 100 kV.
Gel permeation chromatography (GPC) was performed on Waters
2695 Alliance separation model equipped with RI 2414 (410)
detector. The separation of polymers was achieved on Styrogel HR
4E column (Waters, 5 μm, 7.8 mm × 300 mm) at 50 °C using DMF
containing 0.1 M LiBr as mobile phase. The molecular weight of
polymers was calibrated against standard PEG ranging from 112k−
0.4k Dalton. The particle size of polymersome vesicle was measured
on the Malvern Zetasizer Nano ZS by dynamic light scattering (DLS).
Synthesis of O-Acetyl-L-Serine N-Carboxyanhydride (2). The
monomer AcO-L-serine-NCA (2) is synthesized from AcO-L-serine
(1) according to reports.34,35 Briefly, O-acetyl-L-serine (5 g, 34 mmol)
was suspended in 200 mL of dry THF, followed by adding triphosgene
(3.92 g, 17 mmol). The reaction mixture was stirred at 48 °C for 2 h.
The suspension gradually turned clear, which indicated that AcO-L-
serine was consumed and reaction completed. After cooled to room
temperature, the reaction mixture was concentrated under vacuum to
give crude compound 2. The crude product was purified by silica gel
chromatography (the silica gel was dried at 140 °C under vacuum for 8
h before use) using petroleum ether/EtOAc (v/v, 2/1 then 1/1) as
eluent. Light yellow oil was obtained with yield of 83%. 1H NMR (300
MHz, CDCl3): δ 7.14 (s, 1H), 4.67 (s, 1H), 4.60 (d, J = 12 Hz, 1H),
4.32 (d, J = 12 Hz, 1H), 2.11 (s, 3H).
Synthesis of PEG-Poly(AcO-Ser) (3). The diblock copolymer was
synthesized by amine-initiated ring open polymerization.36,37 PEG2000-
NH2 (0.925 g, 0.46 mmol) was added into 80 mL of dry DMSO. The
mixture was stirred at room temperature until it was completely
dissolved. The monomer (2) solution (4.8 g in 10 mL of dry DMSO)
was then quickly added into the reaction. The polymerization was
carried out under vacuum at room temperature for 48 h (vacuum can
remove byproduct CO2 from viscous reaction mixture and facilitate
polymerization). The viscosity of the reaction mixture gradually
increased over reaction time. The product 3 was precipitated from the
reaction by 400 mL of diethyl ether. The crude polymer 3 was
dissolved in 100 mL of water and directly used for next-step reaction.
For NMR characterization, a small portion of reaction mixture was
subjected to dialysis (Spectra/Por, molecular weight cutoff: 1000 Da)
against water for 24 h with frequent water change. The resulting
suspension was lyophilized, dried and characterized by NMR. As for
PEG-Poly(AcO-Serine)34,
1H NMR (300 MHz, DMSO-d6): δ 8.33 (s,
13H), 4.62 (s, 16H), 4.13 (s, 34H), 3.50 (s, 180H), 1.98 (s, 54H).
Figure 1. Schematic of the enzyme-based glucose-responsive nano-
vesicle. (A) GOx converts glucose into gluconic acid and acidifies the
aqueous core of polymersome nanovesicle, leading to hydrolysis of the
polymeric bilayer shell and subsequent dissociation of vesicles. (B)
The chemical structure of the pH-sensitive diblock copolymer PEG-
poly(Ser-Ketal), which can be hydrolyzed into water-soluble PEG-
polyserine and acetone/ethanol in an acidic environment.
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PEG-Polyserine (4). Polymer 3 (crude product from last step) was
suspended in 100 mL of distilled water. The viscous suspension was
stirred at room temperature and blowed with nitrogen gas for 30 min
to remove the trace diethyl ether (the diethyl ether can reduce the
aqueous solubility of polymer 4 and decrease the hydrolysis rate).
Lithium hydroxide (1.3 g, 31 mmol) was added into the reaction and
the reaction was stirred at room temperature for 1.5 h. When the
reaction mixture completely turned clear, 2 N HCl solution was added
to neutralize the reaction solution. The reaction mixture was then
transferred to a dialysis tubing (Spectra Lab, MWCO: 1000 Da) and
dialysis against water for 40 h. The resulting solution was lyophilized
and dried in the CaCl2 desiccators to give pure polymer 4 (1.74 g, two-
step yield: 36%). Mw, 4980 g/mol; Mn, 4057; Mw/Mn, 1.22.
1H NMR
(300 MHz, D2O): δ 4.50 (br s, 13H), 3.88 (br s, 30H), 3.67 (s, 180H).
Synthesis of PEG-Poly(Ser-ketal) (5). In the 50 mL of flask,
polymer 4 (400 mg), and pyridinium p-toluenesulfonate (PPTS, 50
mg, mmol) was added into 20 mL of dry chloroform. The suspension
was sonicated in ultrasonic tank until the fine polymer powder is
uniformly dispersed. 2-Ethoxy-1-propene (1.2 mL) was added into the
reaction. The suspension gradually turned clear in 3 h (if it did not
turn clear, resonicate the reaction on water tank for couple minutes).
After stirred at room temperature for another 13 h, the reaction was
stopped by adding 300 μL of triethylamine. The solvent was removed
by the rotary evaporator. The residue was mixed with 50 mL of diethyl
ether. The white precipitate was collected by centrifuge and washed
with diethyl ether and water, respectively. The resulting polymer was
dried in CaCl2 desiccators under vacuum for 3 days before use (yield:
60−80%). To prepare sample for 1H NMR analysis, the residue from
reaction was mixed with 10 mL of water to form the polymersome
which was then dialysis against water to remove impurities. The
purified polymer was lyophilized and dried in CaCl2 desiccators
overnight before 1H NMR analysis. 1H NMR (300 MHz, DMSO-d6):
δ 8.12 (br s, 8H), 4.55 (br s, 5H), 3.5 (s, 180H), 1.23 (br s, 98H), 1.03
(br, 64H).
1H NMR Determination of Hydroxyl Coverage. A total of 7 mg
of polymer 5 were placed in 1.5 mL of microcentrifuge tube and 0.5
mL of deuterated water (D2O) was added. The polymer was
suspended into D2O by pipet up and down several times and then
transferred into a NMR tube. DCl solution (37% in D2O, 100 or 50
μL) was added into the tube. After capping and sealing the tube with
parafilm, the tube was vortexed for 1 min and kept at room
temperature for 10 min before 1H NMR analysis. Hydroxyl coverage
was determined by comparing the integration of acetone peaks,
ethanol peaks, and PEG-polyserine peaks. All the chemical shifts were
slightly moved to the upfield due to DCl (higher concentration, move
further). The integrations were normalized to the number of protons
on each molecule.
Preparation of Polymersome Nanovesicle. The polymersome
vesicle was prepared by the solvent evaporation method modified from
Marsden et al’s report.3 Briefly, 50 mg of PEG-poly(Ser-ketal) (dry in
desiccators is essential for nanovesicle preparation and insulin
encapsulation) was dissolved in 1.5 mL of THF (it takes couple
hours). A total of 3 mL of aqueous insulin solution (60 mg/mL)
containing GOx/CAT (6 mg/1.5 mg), were slowly added into the
polymer solution during vortex. The mixture was then transferred to
the flask and stirred at 750 rpm in a chemical fume, during which the
nitrogen gas slowly flowed through the flask to accelerate THF
evaporation. After the removal of THF (it takes around 5 min), the
polymersome suspension in the flask was transferred to micro-
centrifuge tubes and centrifuged for 3 min at 12000g. The pellet was
collected and washed several time with PBS buffer (NaCl, 137 mM;
KCl, 2.7 mM; Na2HPO4, 10 mM; KH2PO4, 2 mM; pH 7.4). The
resulting clean nanovesicle pellet was stored at 4 °C for later study.
The insulin loading capacity of vesicles is determined as 2.5 wt %.
Turbidity Test. The turbidity test was performed according to the
report.22 Briefly, nanovesicle solution (50 mM phosphate buffer, pH =
7.4, 5.0 or 3.0) was placed in the cuvettes. After capping, the cuvettes
were kept at 37 °C and the absorbance at 580 nm was measured at the
indicated time points. The optical transmittance (turbidity) was
calculated using the following equation: Tλ = Iout/Iin = 10
−A, Tλ is the
transmittance, I is the transmitted light intensity, and A is the
absorbance.
pH Titration of Nanovesicle Solution at Different Glucose
Concentration. The insulin and enzymes encapsulated nanovesicles
were suspended in PBS buffer (NaCl, 137 mM; KCl, 2.7 mM;
Na2HPO4, 10 mM; KH2PO4, 2 mM; pH 7.4) at the concentration of
50 mg/mL. Glucose was added into the vesicle suspensions to reach
the final concentrations of 0, 100, and 400 mg/dL, respectively. The
nanovesicle solution was incubated at 37 °C for indicated time with
gentle shaking. The pH of the nanovesicle suspension was monitored
every hour using pH meter (Fisher Scientific, AB15).
In Vitro Release of Insulin from Nanovesicles. Nanovesicle was
mixed with 1 mL of PBS solution with different glucose concentrations
(0, 100, or 400 mg/dL). The mixture was incubated at 37 °C under
gently stirring. At indicated time points, 30 μL of the nanovesicle
mixture was taken out and centrifuged at 12000g for 10 min. A total of
10 μL of the supernatant was collected for analysis. The remaining
mixture was reconstituted with 10 μL of fresh solution and returned
into the incubator to maintain a constant volume. The insulin
concentration was measured using Fluoraldehyde (OPA) Reagent
Solution (Pierce, Rockford, IL). Excitation/emission wavelengths were
set at 360/460 nm. The concentration was calibrated with an insulin
standard curve. As of the pulsatile release study, nanovesicle was first
incubated in 400 mg/dL glucose solution for 2 h. The nanovesicle was
then spun down (12000g for 30 s) and washed once with PBS. The
pellet was suspended in 100 mg/dL glucose solution and incubated at
37 °C for another 2 h. The cycles were repeated several times. The
released insulin was measured using OPA Reagent Solution, as
described above.
In Vivo Studies Using STZ-Induced Diabetic Mice. The in vivo
efficacy of insulin-loaded nanovesicle was evaluated on STZ-induced
adult diabetic mice (male C57B6, Jackson Lab, U.S.A.). The animal
study protocol was approved by the Institutional Animal Care and Use
Committee at North Carolina State University. The blood glucose
(BG) level of mice was monitored using the Clarity GL2Plus glucose
meter (Clarity Diagnostics, Boca Raton, Florida) 2 days before
administration. Mice with stable hyperglycemic state were divided into
three groups (seven mice per group) and subcutaneously adminis-
trated with PBS solution, vesicle with insulin (VS(I)) and vesicle with
enzymes and insulin (VS(E+I)), respectively. In order to make it
injectable, nanovesicle was suspended into 30% PF127 solution and
subcutaneously injected into the dorsum of STZ-induced diabetic mice
to form a thermogel. A total of 250 μL of vesicle/PF127 mixture (v/v,
1/1) was subcutaneously injected into the dorsum of mice with a dose
of 50 mg/kg after anesthesia with isoflurane. The BG level of each
mouse was continuously monitored until the stable hyperglycemia
returned. To confirm the bioactivity of released insulin, insulin
solution (0.1 mg of native insulin or insulin released from nanovesicle
at 400 mg/dL glucose for 6 h) was subcutaneously injected into the
dorsum of STZ-induced diabetes mice. The BG level was monitored
using glucose meter every hour until the stable hyperglycemia
returned. In order to monitor the plasma insulin level in vivo, 25 μL
of blood was collected from the tail vein of mice every other day. The
plasma was isolated and stored at −20 °C until assay. The plasma
insulin concentration was measured using Human Insulin ELISA kit
according to the manufacturer’s protocol (Calbiotech, U.S.A.).
Glucose Tolerance Test. In order to confirm the effective insulin
secretion from nanovesicle in response to high glucose challenge,
glucose tolerance test was performed at 3 days post injection of vesicle
containing insulin and enzyme (VS(E+I)). Briefly, glucose solution in
PBS was intraperitoneally injected into all mice at a dose of 1.5 g/kg.
The BG level was closely monitored for 120 min after injection.
Glucose tolerance test on healthy mice was used as control.
Cytotoxicity Study. The cytotoxicity of bare nanovesicle and its
corresponding degradation products (PEG-polyserine, acetone, and
ethanol) was examined on HeLa cells by MTT assay. Briefly, HeLa
cells were seeded in 96-well plate at a density of 7000 cells per well.
After 12 h, series dilutions of compounds (nanovesicle, PEG-
polyserine, acetone, and ethanol) ranging from 1.2 to 0.1 mg/mL
were added into wells. After 24 h incubation, thiazolyl blue solution (5
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mg/mL, Sigma-Aldrich) was added into wells (final concentration: 0.5
mg/mL) and incubated with cells for 2 h. After removing the culture
media, the purple formazan crystal was dissolved in 200 μL of DMSO
plus 25 μL of Sorenson buffer as reported.38,39 The absorbance at 570
nm, which is directly proportional to the viable cell number, was
measured on the Infinite 200 PRO multimode plate reader (Tecan
Group Ltd., Switzerland).
Biocompatibility Evaluation. To evaluate the biocompatibility of
nanovesicle, mice were euthanized via CO2 asphyxiation, and the
injected materials and surrounding tissues were excised. The tissues
were then fixed in 10% formalin, embedded in paraffin, cut into 5 μm
sections, and stained using hematoxylin and eosin (H&E) for
histological analysis.
Statistical Analysis. Student’s t-test or ANOVA were utilized to
determine statistical significance between different groups. A p value
<0.05 was considered to be statistically significant.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of the Ketal-Contain-
ing Diblock Copolymer. The ketal-containing diblock
copolymer was obtained via the amine-initiated ring-open
polymerization (ROP) in five steps with a moderate yield
(Figure 2A). The hydroxyl groups of the serine residue were
first protected by acetyl ester to prevent hydroxyl-mediated
ring-opening of N-carboxy-α-amino acid anhydrides (NCA),
followed by switching to ketal via an acid-catalyzed reaction
with ethoxypropene. We synthesized a series of diblock
copolymer PEG-poly(AcO-Ser)n in DMSO by ROP. As
expected, under a standard reaction condition, the Poly(AcO-
Ser) block showed a gradual growth over changes of the
monomer/initiator ratio (M/I ratio), indicating the controll-
ability of the polymerization (Figure S2). PEG-poly(AcO-
Ser)34, obtained from M/I = 60/1 (the low degree of
polymerization is due to the low activity of amine initiator),
was selected for the further study due to its optimal
hydrophobic/hydrophilic block ratio for achieving a high-
quality of vesicle assembly.31 Hydroxyl groups of the serine
residue were then deprotected to obtain PEG-polyserine34
(Mw= 4,980 g/mol; Mw/Mn = 1.22; Figure S3) and then
conjugated with ketal groups, which are hydrophobic and acid-
sensitive. The conversion of hydroxyl to ketal groups through
reaction with ethoxypropene was gradually proceeded over the
course of reaction time as determined by 1H NMR (Figure 2B).
The maximal conversion was achieved at the reaction time of
over 16 h where the hydoxyl coverage was determined as 84%.
Instead of the cyclic acetal,40 the acyclic acetals dominated the
ketal population of PEG-polyserine during the whole reaction
course, as evidenced by approximately 1:1 ratio of acetone/
ethanol generated from the deuterated hydrogen chloride
(DCl)-induced ketal hydrolysis at all the reaction time points
(Figure S4).
Polymersome Vesicle Assembly and Characterization.
To assemble the obtained amphiphilic PEG-poly(Ser-ketal)
into the vesicles with encapsulated cargoes, a solvent
evaporation method was applied.41 As displayed in Figure 3A,
the transmission electron microscopy (TEM) image revealed
that the resulting vesicles with insulin and enzymes have a
spherical structure and a well-dispersed particle size. The
average diameter determined by dynamic light scattering (DLS)
was 324 nm (Figure 3B), which is consistent with the
observation by TEM. The successful encapsulation of cargoes
was further confirmed by the confocal laser scanning
microscopy imaging of the vesicles with the Oregon Green
488 labeled insulin (Figure S5). The catalytic bioactivity of the
encapsulated enzymes GOx/CAT was well preserved during
the nanovesicle preparation (Figure S6). The insulin loading
capacity was determined as 2.5 wt % (compared to the diblock
copolymer weight). Higher loading capacity was attempted by
increasing the insulin/enzyme concentration during polymer-
some assembly. However, significant insulin precipitation was
observed during the nanovesicle preparation, indicating that 2.5
wt % might reach the maximum of the loading capacity.
Interestingly, 1H NMR spectrum of nanovesicle in Figure S7
only showed the PEG peaks, while poly(Ser-ketal)’s signal was
shielded off, suggesting that this nanovesicle has a “capsid”
consisting of PEG, which screens signals.42,43 Such PEG-based
corona serves as a passivating material for potentially reducing
immune response due to PEG’s chemical inertness and
Figure 2. Synthesis of the novel acid-labile diblock copolymer for nanovesicle assembly. (A) The synthetic route of ketal-containing diblock
copolymer. (B) Ketal substitution on PEG-polyserine changes over the course of reaction time, as determined by 1H NMR after DCl-induced
hydrolysis of ketal groups.
Figure 3. Characterization of polymersome nanovesicles. (A) TEM
image of polymersome nanovesicle formed by PEG-poly(Ser-ketal).
Scale bar: 500 nm. (B) Size distribution of vesicle encapsulated with
insulin and enzymes examined by DLS.
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resistance to protein.44 Furthermore, because the membrane is
composed of a high molecular weight polymer, the vesicles have
robust mechanical stability that can prevent from premature
loss of their cargoes.31,45 No significant leakage of insulin or
obvious morphological change was detected at 4 °C for one
month.
To assess acid-responsive capability of the vesicles, the bare
nanovesicle was first examined by measuring the turbidity of
nanovesicle solution under different pH conditions at 37 °C
(Figure 4A). The optical transmittance of the nanovesicle
suspension at pH 7.4, 5.0, and 3.0 was monitored at the
absorbance wavelength of 580 nm over time. The turbidity of
the nanovesicle solution rapidly decreased at pH 3.0 and 5.0, a
result of the hydrolysis of the diblock copolymer, followed by
the dissociation of the nanovesicles. In contrast, the vesicle was
stable at pH 7.4 and no noticeable turbidity change was
observed over 30 h. To enable this pH-sensitive vesicle to
respond toward glucose, GOx/CAT was incorporated to
provide the enzyme-mediated pH stimulus. The cargo-loaded
vesicles were tested in PBS buffer with different glucose
concentrations, including a typical hyperglycemic level (400
mg/dL) and a normal level (100 mg/dL). As shown in Figure
4B, the vesicles exposed to the hyperglycemic level exhibited a
remarkable pH stimulus. The pH value of the nanovesicle
solution steadily decreases to 4.5 in 8 h, a result of the
enzymatic conversion of glucose to gluconic acid. In contrast,
an insignificant decline of pH value was recorded in the samples
with no glucose or 100 mg/dL glucose, validating that the pH
stimulus provided by enzymes was effectively correlated with
the glucose concentration.
In Vitro Glucose-Responsive Release of Insulin from
the Nanovesicle Encapsulating Insulin and Enzymes. We
next analyzed the in vitro insulin release profile of the vesicles
in response to different glucose levels. As shown in Figure 5A, a
rapid insulin release profile was achieved for the sample
exposed to the hyperglycemic solution. In contrast, only a small
amount of insulin was released from vesicles in either the 100
mg/dL glucose solution or the glucose-free PBS buffer over 12
h. Such a basal release rate of insulin at normoglycemic level is
also desirable in insulin-dependent therapy to manage the
blood-glucose fluctuations.11 The insulin release speed in
Figure 5A is directly related to the ketal hydrolysis of the
diblock copolymer, which is controlled by the pH stimulus of
glucose metabolism. The proton accumulation in the initial
state (0−1.5 h) is relatively low, resulting in a relatively flat
release curve in the first 1.5 h. However, 3 h accumulation of
proton dropped down the pH value of polymersome solution
to ∼5.5, which was acidic enough to trigger bulk ketal
hydrolysis with consequent fast insulin release. More
importantly, a typical pulsatile insulin release pattern was
observed when the vesicles were alternatively exposed between
normoglycemic and hyperglycemic solutions every 2 h for
several cycles (Figure 5B). The release rates responded to the
change of glucose levels of the incubation solution. A maximum
of 3-fold difference in insulin release rate was recorded when
the glucose levels were switched. However, the release rates
associated with hyperglycemic levels gradually decreased over
time. The fading of the “pulsatile ability” can be attributed to
the progressive dissociation of nanovesicle and the subsequent
leakage of enzymes. Collectively, the results substantiated that
the release of insulin from the cargo-encapsulated nanovesicle
undergoes a glucose-mediated biomimetic process.
In Vivo Studies of the Polymersome Nanovesicle for
Type 1 Diabetes Treatment. Utilizing the streptozotocin
(STZ)-induced Type 1 diabetic mice as an animal model, we
next assessed the in vivo efficacy of the insulin-loaded vesicles
for diabetes treatment. We had first demonstrated that the
native human insulin and the insulin released from nanovesicles
upon 400 mg/dL glucose exposure showed similar bioactivity
profiles after administration into diabetic mice at an equivalent
dose (Figure S8), suggesting that the bioactivity of insulin was
highly retained during the formulation preparation and release
test. Mice were grouped and subcutaneously injected with the
PBS solution, vesicles with insulin only (VS(I)) and vesicles
Figure 4. Acid sensitivity of the nanovesicles and its glucose
responsiveness. (A) Optical transmittance profiles of the vesicle
solution under different pH values over time, indicating the mild acid
sensitivity of nanovesicle. (B) Relevant pH changes of the vesicles
incubated with different glucose concentrations: 0, 100, and 400 mg/
dL at 37 °C over time. Enzyme-encapsulated nanovesicle (nano-
reactor) converts the glucose level signal into pH stimulus. Data points
represent mean ± SD (n = 3).
Figure 5. Glucose responsive insulin release of the nanovesicles in
vitro. (A) In vitro accumulated insulin release from the vesicles
incubated in the solutions with different glucose concentrations. (B)
Pulsatile release profile of vesicles presents the rate of insulin release as
a function of glucose concentrations (100 and 400 mg/dL). Data
points represent mean ± SD (n = 3).
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with both insulin and enzymes (VS(E+I)), respectively. In
order to (1) hold the formulation underneath the skin for the
long-term release intention and (2) generate a catalysis center
for synergistically enhanced conversion efficiency,15 30%
Pluronic-127 (PF127), a thermoresponsive and biodegradable
polymer, was mixed with the vesicle pellet to form a suspension
(Figure 6A).46,47 Once subcutaneously injected, the suspension
quickly formed a stable hydrogel, in which nanovesicle were
evenly dispersed (Figures 6B and S9). The BG levels of mice in
each group were monitored using a glucose meter over time. As
summarized in Figure 7A, a rapid decrease of BG level in the
first 12 h was observed in both VS(I) and VS(E+I) groups,
which is likely due to the initial burst release of insulin outside
the vesicles (Figure 7B). After that, the BG level in mice treated
with VS(E+I) maintained in the normoglycemic range (<200
mg/dL for mouse) for up to 5 days. Moreover, the average BG
level was significantly lower than that of the control group
administrated with PBS only for up to 6 days. In contrast, the
BG level of VS (I) group could only maintain in the
normoglycemic state for 1 day, then steadily increased over
time. In the absence of enzymes, VS(I) itself was unable to
undergo acidic degradation for efficient insulin release, resulting
in the noticeably higher BG levels of administrated mice than
those treated with VS(E+I). Correspondingly, the plasma
insulin concentration in the mice treated by VS(I) rapidly
decreased on the next day after administration, while mice in
VS(E+I) treated groups maintained a detectable plasma insulin
level over the 10-day course (Figure 8). The calculated area
under plasma insulin concentration−time curve in VS(E+I)
group was much higher than that in VS(I) group, indicating a
significant pharmacokinetic differences between these two
formulations.
The in vivo glucose responsiveness of insulin/enzyme-loaded
vesicles was verified by a glucose tolerance test at 3 days
postadministration (Figure 9). Mice in VS(E+I) treated group
showed an initial surge in BG concentration upon intra-
peritoneal glucose injection, followed by a quick decrease to
normoglycemic level in 60 min. The glucose responsive profile
in VS(E+I) group was comparable to that in the healthy mice
Figure 6. Injectable nanovesicle formulation made from the
nanovesicle-embedded thermoresponsive matrix. (A) Schematic of in
vivo studies of the glucose-responsive nanovesicle toward STZ-
induced type 1 diabetic mice for regulation of the BG levels. (B)
Nanovesicle integrated with thermoresponsive PF127 solution
immediately formed a hydrogel at 37 °C (upper) in vitro and 3 min
after subcutaneous injection (lower).
Figure 7. In vivo glucose regulation of nanovesicles on STZ-induced diabetic mice. (A) The BG levels of STZ-induced diabetic mice after treatment
with PBS solution, vesicles encapsulating both enzyme and insulin (VS(E+I)) and vesicles encapsulating insulin only (VS(I)). *p < 0.01 compared to
PBS group. (B) The BG level was continuously monitored in the first 12 h after administration of PBS solution, VS(E+I) and VS(I) in the STZ-
induced diabetic mice. Data points represent mean ± SD (n = 7).
Figure 8. Changes of the plasma insulin concentration over time after
administration. Data points represent mean ± SD (n = 7).
Figure 9. In vivo glucose tolerance test toward diabetic mice 3 days
post injection of VS(E+I) in comparison with the healthy control
mice. Data points represent mean ± SD (n = 3).
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control group. Moreover, the bare vesicles and their relevant
degradation products (ethanol and acetone) did not show
significant toxicity within all the studied concentrations (Figure
10A−D). The injected formulation including PF127 completely
degraded in 4 weeks after administration, and no inflammatory
region or fibrotic encapsulation was observed (Figure 10E,F).
■ CONCLUSION
In summary, a new biomimetic insulin delivery strategy has
been developed using glucose-responsive polymersome nano-
vesicle. The enzymatic conversion of glucose into gluconic acid
in the aqueous core of vesicles reduces the local pH, resulting in
the hydrolysis of the mildly acidic-degradable components of
assembled polymers and the dissociation of vesicles, therefore
facilitating the release of encapsulated insulin. The in vivo
studies demonstrated that this nanovesicle is highly biocompat-
ible and effective in regulating blood glucose levels for a long
period of time. Further study will be essential to optimize the
glucose response sensitivity and achieve dynamic regulation of
the BG levels under in vivo conditions. Additionally, we believe
that this acid-sensitive formulation may be extended to allow
delivery of other therapeutic agents, the release of which can be




Experimental details of the polymer synthesis, characterization,
toxicity assay and histology test. This material is available free
of charge via the Internet at http://pubs.acs.org.
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Figure 10. Biocompatibility study of the nanovesicles in vitro and in vivo. Cytotoxicity assay of bare vesicle (A) and its degradation products, PEG-
polyserine (B), acetone (C), and ethanol (D) toward HeLa cells for 24 h. H&E stained sections of subcutaneously injected PBS (E) or VS(E+I) (F)
with surrounding tissue after 4 weeks, respectively. Scale bar: 200 μm.
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Frećhet, J. M. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 5497−5502.
(41) Marsden, H. R.; Gabrielli, L.; Kros, A. Polym. Chem. 2010, 1,
1512−1518.
(42) Ding, M.; Song, N.; He, X.; Li, J.; Zhou, L.; Tan, H.; Fu, Q.; Gu,
Q. ACS Nano 2013, 7, 1918−1928.
(43) Cuong, N.-V.; Li, Y.-L.; Hsieh, M.-F. J. Mater. Chem. 2012, 22,
1006−1020.
(44) Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.;
Langer, R. Nat. Nanotechnol. 2007, 2, 751−760.
(45) Discher, B. M.; Won, Y.-Y.; Ege, D. S.; Lee, J. C.; Bates, F. S.;
Discher, D. E.; Hammer, D. A. Science 1999, 284, 1143−1146.
(46) Jeong, B.; Kim, S. W.; Bae, Y. H. Adv. Drug Delivery Rev. 2012,
64, 154−162.
(47) Morikawa, K.; Okada, F.; Hosokawa, M.; Kobayashi, H. Cancer
Res. 1987, 47, 37−41.
(48) Gu, Z.; Biswas, A.; Zhao, M.; Tang, Y. Chem. Soc. Rev. 2011, 40,
3638−3655.
(49) Tai, W.; Mahato, R.; Cheng, K. J. Controlled Release 2010, 146,
264−275.
(50) Mo, R.; Jiang, T.; Gu, Z. Angew. Chem., Int. Ed. 2014,
DOI: 10.1002/anie.201400268.
Biomacromolecules Article
dx.doi.org/10.1021/bm500364a | Biomacromolecules 2014, 15, 3495−35023502
